Evaluation of the perioperative period safety of improved transurethral plasma kinetic enucleation of prostate in high-risk benign prostatic hyperplasia patients with coronary heart disease

Abstract

Objective To evaluate the perioperative period safety of improved transurethral plasma kinetic enucleation of prostate (TUPKEP) in high-risk benign prostatic hyperplasia (BPH) patients with coronary heart disease (CHD). Methods One hundred and twenty-eight BPH patients were selected, 24 patients had CHD (with CHD group), among whom 10 patients were given transurethral vapor-resection of prostate (TUVP), and 14 patients were given improved TUPKEP; 104 patients didn't have CHD, among whom 22 patients were given TUVP, and 82 patients were given improved TUPKEP. The serum endothelin (ET)-1 was measured by specific radioimmunoassay at preoperative 2 h and postoperative 1, 2, 6 d, and complication was observed. Results All the patients were cured by operation, and left hospital smoothly. There were no statistical differences in the preoperative 2 h serum ET-1 in with CHD group and without CHD group (including all TUVP patients and improved TUPKEP patients) (P >0.05). The postoperative 1 and 2 d serum ET-1 levels of TUVP patients were significantly higher than those of improved TUPKEP patients, in with CHD group: (114.09 ± 15.33) ng/L vs. (94.77 ± 12.14) ng/L and (99.67 ± 9.87) ng/L vs. (88.21 ± 9.55) ng/L; in without CHD group: (70.21 ± 12.44) ng/L vs. (53.67 ± 9.02) ng/L and (61.18 ± 9.52) ng/L vs. (48.54 ± 9.15) ng/L, and there were statistical differences (P 0.05). In with CHD group, 5 patients had ischemic ST-T change in the early postoperative period, and 3 patients had angina pectoris. They all were promptly treated, and the events were controlled. Serious complications did not present such as acute myocardial infarction (AMI), acute heart failure and sudden cardiac death, etc. Conclusions The postoperative BPH patients have vascular endothelial injury catholically, especially the high-risk patients with CHD. Furthermore, it might be one of the causes of the postoperative adverse cardiovascular events. Compared with TUVP, improved TUPKEP has a minor impact on vascular endothelial function, and it can reduce the postoperative adverse cardiovascular events in the BPH patients with CHD. Improved TUPKEP is a relatively safer surgical method for high-risk BPH with CHD. Key words: Transurethral resection of prostate; Prostatic hyperplasia; Endothelin-1; Transurethral plasma kineticenuc leation of prostate